Business Context and Reporting Period
This Form 8-K filing by Dermata Therapeutics, Inc. (DRMA) reports a change in the company's independent registered public accounting firm. The report date is January 30, 2026, with the dismissal of the prior firm effective January 31, 2026, and the appointment of the new firm approved on February 2, 2026.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the current period. However, it notes that the audit reports for the fiscal years ended December 31, 2024, and 2023 included an explanatory paragraph relating to substantial doubt about the Company's ability to continue as a going concern.
Material Changes
- Dismissal of Accountant: Baker Tilly US, LLP (formerly Moss Adams LLP) was dismissed as the independent registered public accounting firm, effective January 31, 2026.
- Appointment of New Accountant: CBIZ CPAs P.C. (formerly Mayer Hoffman McCann P.C.) was appointed as the new independent registered public accounting firm on February 2, 2026.
- Historical Relationship: CBIZ CPAs previously served as the company's auditor from 2016 to 2023.
Management Commentary, Risks, and Contingencies
The Audit Committee approved both the dismissal and the appointment. The company confirmed there were no disagreements with Baker Tilly regarding accounting principles, practices, or audit scope during the two most recent fiscal years or the interim period through January 31, 2026. Similarly, no "reportable events" occurred during this timeframe. The filing references the prior "going concern" qualification but does not provide new management commentary on the company's financial outlook or specific risks beyond the auditor change.
Investor Verification Checklist
- Verify the reasons for the dismissal of Baker Tilly US, LLP, given the prior "going concern" qualification in their audit reports.
- Review the letter from Baker Tilly US, LLP (Exhibit 16.1) to confirm their stance on the dismissal and any potential undisclosed disagreements.
- Assess the company's current liquidity position and capital raise plans in light of the previously noted substantial doubt about its ability to continue as a going concern.
- Confirm the transition timeline for CBIZ CPAs P.C. to ensure no gaps in audit coverage for upcoming reporting periods.